5-Methyl-4-isoxazole carboxylic acid 42831-50-5 Leflunomide intermediate white powder
42831-50-5
shanghai
1kg/bag
2023-03-03
calcium L-5-methyltetrahydrofolate
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
5-Methyl-4-isoxazolecarboxylic acid
Other Name:5-Methyl-4-isoxazolecarboxylic acid, Tech.;5-methylisoxazole-4-carboxylic acid(SALTDATA: FREE);Methylisoxazole-4-carboxylic;LeflunoMide EP IMpurity D;4-Carboxy-5-methylisoxazole ,4-Carboxy-5-methyl-1,2-oxazole;5-Methylisoxazole-4-carboxylic acid, 99%, 99%;Leflunomide Impurity D;5-Methyl-isoxazol-4-carboxylic acid
CAS No.:42831-50-5
Molecular Formula:C5H5NO3
InChIKeys:VQBXUKGMJCPBMF-UHFFFAOYSA-N
Molecular Weight:127.1
Exact Mass:127.10
BRN:116000
EC Number:700-400-1
UNII:BL2Q213Q2M
DSSTox ID:DTXSID20195503
Color/Form:White to Pale Brown
HScode:29349990
Categories:
Characteristics-
Density:
1.348±0.06 g/cm3(Predicted)
Melting Point:144-148 °C(lit.)
Boiling Point:308.3±22.0 °C(Predicted)
Flammability characteristics:Non flammable
PKA:2.85±0.25(Predicted)
Critical Temperature & Pressure:Sealed in dry,Room Temperature
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
calcium L-5-methyltetrahydrofolate
-
Location:
No.111,Qinxin Rd,Donggang Town,Xishan Dist,Wuxi,China.
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A
-
Average lead Time:
300
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
101-200
-
Year of Establishment:
2004
-
Certifications:
KOSEHR
Wuxi Taxus Pharmaceutical Co.,Ltd was established in 2004,and a bio-pharmaceutical company under the HODO Group which is the top 500 private enterprises . It is mainly engaged in the research, development, production and sales of paclitaxel-based anti-tumor drugs. The complete industrial chain was established,from the cultivation of yew resources to the processing of yew branches and leaves, paclitaxel primary products, paclitaxel series of raw materials and intermediates to preparations . Products include paclitaxel, docetaxel, cabazitaxel, 10-DAB, oxaliplatin, dresian hydrochloride, allopurinol, L-5-methylfolate, L-5-methylfolate, etc. API, and paclitaxel injection.
The company has strong technical strength. In 2018, the company established the Hongdoushan International Pharmaceutical Research and Development Company in New York, focusing on the research and development and introduction of anticancer drugs. At present, the Hongdoushan research and development center hires the Doctor returned from abroad to lead the research and development of new products, and currently has more than 30 senior engineers. What’s more, the R&D Center has established close cooperative relations with Jiangsu Academy of Agricultural Sciences, Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Tsinghua University, and foreign research institutes.
The company's paclitaxel API has obtained the US DMF registration number (25759), and is registered in Korea, India, Iran, Russia, Belarus and other countries. It is sold at home and abroad, mainly exported to India, South America, Russia, Egypt and other countries and regions,and praised
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product